10x Genomics (NASDAQ:TXG) Issues Quarterly Earnings Results

10x Genomics (NASDAQ:TXG) announced its quarterly earnings results on Wednesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08), Zacks reports. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. 10x Genomics updated its FY 2025 guidance to EPS.

10x Genomics Stock Performance

Shares of NASDAQ:TXG traded up $0.18 during trading hours on Wednesday, hitting $12.00. 4,201,812 shares of the company’s stock traded hands, compared to its average volume of 2,328,019. The company’s fifty day simple moving average is $14.90 and its two-hundred day simple moving average is $17.50. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -7.84 and a beta of 1.85. 10x Genomics has a 52 week low of $11.55 and a 52 week high of $51.22.

Analyst Upgrades and Downgrades

TXG has been the topic of several recent research reports. Citigroup cut their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th. Morgan Stanley cut their price target on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. JPMorgan Chase & Co. reduced their price objective on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Barclays lowered their target price on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, The Goldman Sachs Group reduced their price target on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.